{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"}]}],"title":"Creatinine, high, n=15, 21, 44, 65"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}]}],"title":"Creatinine, low, n=15, 21, 44, 65"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"46"}]}],"title":"Creatinine Clearance Derived, high, n=15, 21,44,65"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}],"title":"Creatinine Clearance Derived, low, n=15, 21,44,65"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"18"}]}],"title":"Protein/Creatinine, high, n=12, 19, 38, 58"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Protein/Creatinine, low, n=12, 19, 38, 58"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"}]}],"title":"Urea, high, n=15, 21, 44, 65"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"11"}]}],"title":"Urea, low, n=15, 21, 44, 65"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \\[ ml/min\\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \\[mg/mmol\\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment","groups":[{"description":"Participants aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3-1 to 5 years) received eltrombopag for 24 weeks. The starting dose for cohort 1 was eltrombopag 25 mg, (East Asian ancestry: 12.5mg, QD). For cohort 2 starting dose was based on the body weight (Weight \\<27 kg: 25 mg QD, Weight \\>=27 kg: 50 mg QD; east Asian ancestry subjects Weight \\<27 kg: 12.5 mg QD, Weight \\>=27 kg: 25 mg QD). For cohort 1 and 2 maximum dose allowed was 75mg. For cohort 3 starting dose was 0.7 mg/kg, QD and the dose calculations were based on the body weight. For all participants individual dose titration was allowed based upon platelet response.","id":"OG000","title":"Part 1 (Dose-Finding Period)"},{"description":"Participants aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3- 1 to 5 years) received eltrombopag matching placebo for 7 weeks.","id":"OG001","title":"Part 2 (Randomized Period) -Placebo"},{"description":"Participants aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3-1 to 5 years) received eltrombopag for 7 weeks. The starting dose for cohort 1 was eltrombopag 25 mg, (East Asian ancestry: 12.5mg, QD). For cohort 2 starting dose was based on the body weight (Weight \\<27 kg: 25 mg QD, Weight \\>=27 kg: 50 mg QD; east Asian ancestry subjects Weight \\<27 kg: 12.5 mg QD, Weight \\>=27 kg: 25 mg QD). For cohort 1 and 2 maximum dose allowed was 75mg. For cohort 3 starting dose was 0.7 mg/kg, QD and the dose calculations were based on the body weight. For all participants individual dose titration was allowed based upon platelet response.","id":"OG002","title":"Part 2 (Randomized Period) - Eltrombopag"},{"description":"Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3: 1 to 5 years), completing Part 2 of the study received an Open -Label treatment of eltrombopag administered as a tablet or dry powder for oral suspension in Part 2/3. Par who received eltrombopag during the Randomized Period continued on the same dose, unless adjustments were warranted according to the dosing guidelines, for 17 additional weeks (for a total of 24 weeks of treatment). Par who received placebo during the Randomized Period followed the starting doses for each age Cohort specified for Part 2, and received a total of 24 weeks of eltrombopag treatment.","id":"OG003","title":"Part 2/ 3 (Eltrombopag Open-Label Period)"}],"paramType":"NUMBER","populationDescription":"Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Safety Population.","reportingStatus":"POSTED","timeFrame":"Post-Baseline from Week 1 through Follow-up up to Study Week 35","title":"Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3","type":"SECONDARY","unitOfMeasure":"Participants"}